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Abstract
Introduction: Several strategies are still being introduced to 
cardiac surgery techniques to reduce the signs of the inflam-
matory response and oxidative stress. Many efforts have been 
made to develop the best possible method for myocardial pro-
tection.
Aim: To assess the effect of the cardioplegia strategy on the 
systemic inflammatory response and oxidative stress.
Material and methods: A group of 238 consecutive, elective on-
pump coronary artery bypass graft patients (CABG; 183 men, 
aged 64.6 ±8.1 years) were prospectively studied. Patients were 
enrolled in two groups: with warm blood cardioplegia (n = 124) 
and with cold crystalloid cardioplegia (n = 114). In each group, 
pre- and postoperative levels of plasma C-reactive protein, 
fibrinogen, interleukin 6 and 8-iso-prostaglandin F2α (8-iso-
PGF2α) were measured.
Results: All studied markers significantly increased 18–36 h fol-
lowing CABG and then decreased in 5–7 postoperative days 
but remained above baseline levels. No differences in terms 
of studied markers and clinical outcomes were noted for the 
different types of cardioplegia. Regression analysis showed 
a significant correlation between preoperative level of oxida-
tive stress measured by 8-iso-PGF2α and postoperative myo-
cardial infarction as well as in-hospital cardiovascular death 
(p = 0.047 and p = 0.041 respectively).
Conclusions: This study extends previous reports by showing 
that the type of cardioplegia does not affect the systemic in-
flammatory response or oxidative stress, which are associated 
with the CABG procedure. It might be speculated that preopera-
tive screening of oxidative stress could be helpful in identifying 
patients at increased risk of an unfavorable course after CABG.
Key words: coronary artery bypass graft, cardioplegia, inflam-
matory response, oxidative stress.
Streszczenie
Wstęp: Ciągle wprowadzane są nowe techniki chirurgiczne 
i anestezjologiczne mające na celu zmniejszenie odpowiedzi 
zapalnej i stresu oksydacyjnego po operacjach kardiochirur-
gicznych. Podjęto wiele badań, których celem było stworzenie 
możliwie najlepszej metody ochrony mięśnia sercowego.
Cel: Ocena wpływu metody ochrony mięśnia sercowego na od-
powiedź zapalną i stres oksydacyjny.
Materiał i metody: W badaniu prospektywnym wzięło udział 
238 kolejnych chorych poddanych planowemu pomostowaniu 
aortalno-wieńcowemu (CABG; 183 mężczyzn, średni wiek: 64,6 
±8,1 roku). Pacjenci zostali przydzieleni do dwóch grup – 
w pierwszej wykorzystano ciepłą kardiopleginę krwistą (n = 124), 
a w drugiej chłodną kardiopleginę krystaliczną (n = 114). W każ-
dej grupie oznaczono przed- i pooperacyjnie poziomy białka 
C-reaktywnego, fibrynogenu, interleukiny 6 oraz 8-iso-prosta-
glandyny F2α (8-iso-PGF2α).
Wyniki: Wszystkie badane markery wzrosły istotnie pomię-
dzy 18. a 36. godziną po CABG, a następnie zmniejszyły się 
w 5.–7. dobie po operacji, lecz ich poziom ciągle pozostawał 
wyższy niż wyjściowy. Nie odnotowano istotnych różnic w za-
kresie badanych markerów oraz w przebiegu klinicznym po-
między badanymi grupami. Analiza regresji wykazała istotną 
korelację pomiędzy przedoperacyjnym poziomem stresu oksy-
dacyjnego, mierzonym 8-iso-PGF2α, oraz okołooperacyjnym 
zawałem mięśnia sercowego i śmiertelnością szpitalną (odpo-
wiednio p = 0,047 i p = 0,041).
Wnioski: Przedstawione badanie poszerza wcześniejsze donie-
sienia, że rodzaj kardiopleginy u pacjentów poddanych CABG 
nie wpływa istotnie na poziom odpowiedzi zapalnej oraz stresu 
oksydacyjnego. Przedoperacyjny pomiar stresu oksydacyjnego 
może być pomocny w rozpoznaniu pacjentów o zwiększonym 
ryzyku niekorzystnego przebiegu pooperacyjnego.
Słowa kluczowe: pomostowanie aortalno-wieńcowe, kardio-
plegia, odpowiedź zapalna, stres oksydacyjny.
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Introduction
The protective effect of cardioplegia is related to myo-
cardium metabolism reduction, thereby increasing cardiac 
capacity for prolonged ischemia during cardiosurgery pro-
cedures. Although the heart is protected during surgery by 
cardioplegic solution, temporary myocardial ischemia and 
then reperfusion result in exacerbation of the systemic 
inflammatory response, which is a result of, among other 
things, surgical trauma, manipulation of the heart, cardio-
pulmonary bypass, pericardial suction or genetic predis-
posal [1, 2]. Despite cardioplegia, myocardial production 
of reactive oxygen species still occurs. Imbalance between 
reactive oxygen species generation and elimination results 
in oxidative stress, which is an important cause of the sys-
temic inflammatory response and in consequence leads to 
ischemia-reperfusion injury [2].
Since Denis Melrose introduced elective, chemical car-
diac arrest in the 1950s, many efforts have been made to 
develop the best possible method for myocardial protection. 
The two main types of cardioplegic solutions predominantly 
used in coronary artery bypass graft (CABG) surgery are 
warm blood cardioplegia and cold crystalloid cardioplegia. 
There is an ongoing discussion about the effectiveness and 
side effects of cardioplegic solutions [3]. To our knowledge, 
there are few studies comparing the inflammatory response 
and oxidative stress in different type of cardioplegia [4–6]. 
Aim
Therefore, the aim of this study was to analyze the im-
pact of cardioplegia strategy on C-reactive protein (CRP) 
and fibrinogen, as well as interleukin 6 (iL-6) as the main 
stimulus for production of these acute-phase proteins in the 
liver. Furthermore, we evaluated the influence of the type 
of cardioplegia on 8-iso-prostaglandin F2α (8-iso-PGF2α) 
as a marker of oxidative stress.
Material and methods
Patients 
The study was performed in accordance with the Dec-
laration of Helsinki and with the consensus guidelines 
expressed by the sTROBe statement. The patients were 
recruited between January and March 2008. We studied 
238 consecutive patients undergoing primary, elective and 
isolated CABG using cardiopulmonary bypass (CPB). A sub-
set of this cohort was analyzed in our previous studies [7, 
8]. indications for CABG were consistent with the european 
society of Cardiology and the european Association for Car-
dio-Thoracic Surgery guidelines on myocardial revascular-
ization [9]. The exclusion criteria were signs or symptoms 
of acute infections, presence of extensive dental disease, 
concomitant diseases such as autoimmune disorders or 
cancer, acute coronary syndrome, or percutaneous coronary 
intervention within 1 month before the enrolment, and liver 
or renal insufficiency. Patients were categorized into two 
groups: with warm blood and cold crystalloid cardioplegia. 
The choice of the type of cardioplegia was based on the 
surgeon’s preference. Clinical outcomes showed no asso-
ciations with surgery performance. All data were collected 
prospectively. Additionally, we correlated the perioperative 
values of inflammatory and oxidative stress markers with 
the clinical outcomes after CABG surgery, i.e. postoperative 
myocardial infarction (PMI) and in-hospital cardiovascular 
death. The PMi was defined as a serum creatine kinase-myo-
cardial band (CK-MB) concentration greater than or equal 
to 5 times the upper limit of normal (≥ 85 U/l), and new Q 
waves present, or the CK-MB value had to be greater than 
or equal to 10 times the upper limit of normal (≥ 170 U/l) 
(with or without new Q waves) or new regional wall motion 
abnormalities demonstrated by transesophageal echocar-
diography [10]. In-hospital cardiovascular death was de-
fined as death occurring during the same hospitalization 
period as the CABG surgery. 
Coronary artery bypass graft procedure
Surgical technique, anesthesia and perioperative man-
agement were uniform for all patients. All operations were 
performed on CPB consisting of a nonpulsatile roller pump 
(Jostra Medizintechnik AG, Hirrlingen, Germany) and an in-
line arterial blood filter (Jostra Medizintechnik AG, Hirrlin-
gen, Germany) under moderate systemic hypothermia 
(esophageal temperature, 32ºC). Mean arterial pressure was 
maintained between 40 and 60 mm Hg and CPB blood flow 
was maintained at 2.0–2.4 l/min/m2. Anticoagulation was 
achieved by administration of heparin (500 IU/kg) before the 
onset of CPB and was monitored by means of the activated 
clotting time, which had to be above 400 s during CPB. 
Cardiac arrest was accomplished by administration of 
antegrade, intermittent, cold crystalloid cardioplegia or 
antegrade, intermittent, warm blood cardioplegia. Patients 
obtaining crystalloid cardioplegia were given a first dose 
of 1000 ml of cardioplegia solution through the aortic root 
and were given more cardioplegia if cardiac arrest was not 
achieved. 500 ml of crystalloid cardioplegia was given the 
same way every 40 min or earlier in the case of premature 
heart activity. The cold crystalloid cardioplegia consisted of 
Ringer’s solution (500 ml) to which 2.5 ml of 20% magne-
sium sulfate, 5 ml of 15% potassium chloride, 10 ml of 15% 
mannitol and 5.5 ml of 8.4% sodium hydrogen bicarbonate 
were added. The temperature of the cardioplegic solution 
was maintained at 4°C throughout the entire operative pro-
cedure. In patients with blood cardioplegia, warm (37°C) ox-
ygenated blood was infused into the aortic root. A syringe 
pump containing 15% potassium chloride was connected 
to the cardioplegia circuit. Cardiac arrest was induced at 
a blood flow rate of 300 ml/min by continuous infusion of 
180 ml/h of the syringe pump over a 3-minute time period. 
Cardioplegia was repeated through the aortic root for 2 to 
3 min after the completion of each anastomosis or earlier 
in the case of premature cardiac activity.
Laboratory investigations 
Blood samples for iL-6, fibrinogen, high-sensitivity CRP 
and 8-iso-PGF2α were drawn after an overnight fast, before 
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the start of any surgery-related procedures, 18–36 h after 
CABG (without iL-6) and 5–7 days postoperatively. A com-
mercially available immuno-enzymatic assay was used to 
determine serum iL-6 (R&d systems inc., Minneapolis, usA) 
and plasma 8-iso-PGF2α (Cayman Chemicals, Ann Arbor, 
usA). The minimal detectable iL-6 concentration was 0.03 
pg/ml. High-sensitivity CRP was measured by an immuno-
turbidimetric assay (dade Behring, Marburg, Germany). Fi-
brinogen was determined using the Clauss method [11]. All 
measurements were performed by technicians blinded to 
the origin of the samples. intra- and interassay coefficients 
of variation were < 7%.
Statistical analysis 
Descriptive statistics were described as numbers and 
percentages for categorical variables. Continuous variables 
were presented as mean and standard deviation (±). The 
Shapiro-Wilk test was used to test the normality of con-
tinuous variables. To observe the differences between the 
two independent groups, Student’s t-test (for continuous 
normally distributed variables) or the Mann-Whitney U-test 
(for non-normally distributed variables) were used. The c2 
test or Fisher’s exact test was used to compare distribu-
tions of categorical variables between independent groups. 
The association between the concentrations of analyzed 
markers and PMI or in-hospital death was evaluated by 
logistic regression analysis. No multivariate logistic regres-
sion analysis was performed because of the low number of 
clinical endpoint events. Statistical analysis was performed 
with Statistica 10.0 (StatSoft, Tulsa, USA). Two-sided p-val-
ues of < 0.05 were considered statistically significant.
Results
The mean age for all patients was 64.6 ±8.1 years. One 
hundred twenty-four patients were operated on using 
blood cardioplegia and 114 underwent CABG using crystal-
loid cardioplegia. Patients’ demographic data did not differ 
among groups (Tab. I). Aortic cross clamp time as well as 
CPB time were significantly longer in patients with blood 
cardioplegia (42.8 ±14.2 min vs. 38.9 ±13.8 min, p = 0.037 
and 96.2 ±36.8 min vs. 83.0 ±29.5 min, p = 0.003, respec-
tively), compared with the patients with crystalloid cardio-
plegia. Forty-seven (37.9%) patients with blood cardiople-
gia and 29 (25.4%) subjects with crystalloid cardioplegia 
needed transfusion of ≥ 3 units of blood products during 
the perioperative period (p = 0.039) (Tab. II). 
As shown in Table iii, in the whole group, mean iL-6 in-
creased almost 6 times in 5–7-days after CABG (p < 0.0001). 
Mean fibrinogen increased by 50% 18–36 h after surgery 
(p = 0.01) and then continued to grow by 13% 5–7 days after 
the procedure (p = 0.05). As expected, CRP concentration in-
creased markedly 18–36 h after CABG (p < 0.0001), and then 
decreased by 65% in 5–7 postoperative days (p = 0.001). 
similarly, 8-iso-PGF2α increased by 30% 18–36 h following 
CABG (p = 0.05) and then decreased by 11% in 5–7 days af-
ter CABG (p < 0.0001). No differences in the studied markers 
were noted between the two types of cardioplegia. 
There were no significant differences between ana-
lyzed groups regarding frequencies of occurrence of clinical 
endpoints. Of the 238 patients, 20 (8.4%) patients devel-
oped PMi, 11 (8.9%) patients from the blood cardioplegia 
group and 9 (7.9%) from the crystalloid cardioplegia group 
(p = 0.786). eight (3.4%) patients died during the early post-
operative period due to massive PMi. These were 4 (3.2%) 
patients from the blood cardioplegia group and 4 (3.5%) 
from the crystalloid cardioplegia group (Tab. IV). There were 
no differences in the preprocedural demographic and clini-
cal data between the subjects with clinical endpoints and 
remaining patients (data not shown). Only 8-iso-PGF2α con-
centration was significantly higher in the PMi and in-hospi-
Tab. I. Baseline characteristics of patients
Variable All patients
(N = 238)
Blood cardioplegia
(n = 124)
Crystalloid cardioplegia
(n = 114)
P-value
Age [years] 64.6 ±8.1 64.5 ±8.2 64.6 ±8.3 0.902
Male, n (%) 183 (76.9) 90 (72.6) 93 (81.6) 0.999
Peripheral vascular disease, n (%) 30 (12.6) 14 (11.3) 16 (14.0) 0.524
Diabetes mellitus, n (%) 69 (29.0) 36 (29.0) 33 (28.9) 0.988
Insulin, n (%) 33 (13.9) 19 (15.3) 14 (12.3) 0.515
Hypertension, n (%) 197 (82.8) 104 (83.9) 93 (81.6) 0.640
Previous myocardial infarction, n (%) 197 (82.8) 97 (78.2) 100 (87.7) 0.052
Hypercholesterolemia, n (%) 33 (13.9) 16 (12.9) 17 (14.9) 0.654
BMI [kg/m2] 28.1 ±4.1 28.1 ±4.0 28.0 ±4.1 0.850
LVeF (%) 52.2 ±9.4 52.7 ±9.7 51.5 ±9.0 0.329
Previous PCI, n (%) 29 (12.2) 11 (8.9) 18 (15.8) 0.103
COPD, n (%) 11 (4.6) 7 (5.6) 4 (3.5) 0.433
eurosCORe 1 (points) 3 (2–5) 3 (2–5) 3 (2–5) 0.965
Values are displayed as mean ± standard deviation, number (percentage) or median with inter-quartile range. BMi – body mass index, LVeF – left ventricular ejection 
fraction, PCi – percutaneous coronary interventions, COPd – chronic obstructive pulmonary disease. 
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tal death group both before and after CABG, irrespective of 
the cardioplegia approach used. inflammatory markers did 
not differ between patients with and without clinical end-
points, except iL-6, 5–7 days after the procedure (Tab. iV). 
Regression analysis showed a significant correlation be-
tween preoperative concentration of oxidative stress mea-
sured by 8-iso-PGF2α, and PMI as well as in-hospital cardio-
vascular death (p = 0.047 and p = 0.041, respectively). 
Discussion
Our study compares the impact of warm blood cardio-
plegia versus cold crystalloid cardioplegia on inflammatory 
and oxidative stress markers as well as clinical outcomes 
after CABG. For the assessment of systemic inflamma-
tion, we measured CRP and fibrinogen as well as iL-6 as 
the main stimulus for CRP and fibrinogen production in the 
liver. 8-iso-PGF2α was analyzed as a stable and reliable bio-
marker of oxidative stress. In this study, neither cardiople-
gic solution was found to have a greater effect on inflam-
matory and oxidative stress markers after CABG surgery. 
Both cardioplegic solutions were associated with a similar, 
significant increase in the studied markers after the proce-
dure. Moreover, our study failed to demonstrate any advan-
tage of either cardioplegia in terms of PMI and in-hospital 
mortality. In addition, both clinical endpoints correlated 
only with pre- and postoperative levels of oxidative stress. 
systemic inflammatory response and enhanced reac-
tive oxygen species formation could be a consequence 
of, among other things, surgical trauma, manipulation of 
the heart, cardiopulmonary bypass, pericardial suction or 
genetic predisposal [2]. Cardioplegic heart arrest and then 
reperfusion of the ischemic myocardium after CABG can 
further aggravate oxidative stress and the inflammatory 
response. In the experimental studies, cardiac myocytes, 
when exposed to ischaemia or myocardium arrested by 
cold crystalloid cardioplegia, have been shown to produce 
iL-6 [12–14]. Additionally, iL-6 and reactive oxygen species 
are also produced by the heart during the CABG procedure 
Tab. II. Operative and postoperative characteristics of patients
Variable All patients
(N = 238)
Blood cardioplegia
(n = 124)
Crystalloid cardioplegia
(n = 114)
P-value
Aortic cross-clamp time [min] 40.9 ±14.1 42.8 ±14.2 38.9 ±13.8 0.037
CPB time [min] 89.9 ±34.1 96.2 ±36.8 83.0 ±29.5 0.003
Transfusion (red cells/platelets/plasma) ≥ 3 units, n (%) 76 (31.9) 47 (37.9) 29 (25.4) 0.039
Postoperative drainage [ml] 660 (460–905) 680 (500–930) 665 (465–870) 0.285
PMI, n (%) 20 (8.4) 11 (8.9) 9 (7.9) 0.786
In-hospital cardiovascular death, n (%) 8 (3.4) 4 (3.2) 4 (3.5) 0.903
Values are displayed as mean ± standard deviation, number (percentage) or median with inter-quartile range. CPB – cardiopulmonary bypass, PMi – postoperative 
myocardial infarction.
Tab. III. Changes of studied inflammatory response and oxidative stress parameters after coronary artery bypass graft
Variable All patients
(N = 238)
Blood cardioplegia
(n = 124)
Crystalloid cardioplegia
(n = 114)
P-value
iL-6 [pg/ml]:
 At baseline 2.1 (1.1–4.0) 2.1 (1.0–3.5) 2.1 (1.2–4.2) 0.110
 5–7-days after CABG 14.6 (5.2–23.9) 16.4 (3.9–32.5) 14.0 (5.6–21.3) 0.739
Fibrinogen [g/l]:
At baseline 4.2 ±1.2 4.2 ±1.2 4.2 ±1.1 0.994
18–36 h after CABG 6.3 ±1.7 6.7 ±1.8 5.7 ±1.6 0.479
5–7-days after CABG 7.1 ±1.4 7.1 ±1.5 7.0 ±1.3 0.585
CRP [mg/l]:
At baseline 2.3 (1.5–4.7) 2.3 (1.5–4.8) 2.2 (1.6–4.6) 0.415
18–36 h after CABG 145.5 (102.2–183.8) 153.3 (122.4–180.2) 141.1 (89.8–195.4) 0.861
5–7-days after CABG 50.3 (28.3–80.5) 45.5 (27.1–85.9) 51.7 (29.9–70.1) 0.770
8-iso-PGF2α [pg/ml]:
At baseline 358.4 ±39.3 358.3 ±38.2 358.4 ±41.3 0.994
18–36 h after CABG 466.9 ±42.5 466.4 ±42.9 467.7 ±42.3 0.867
5–7-days after CABG 417.2 ±47.8 424.1 ±49.1 410.4 ±46.0 0.189
Values are displayed as mean ± standard deviation or median with inter-quartile range. iL-6 – interleukin 6, CABG – coronary artery bypass graft surgery, CRP – C-reactive 
protein, 8-iso-PGF2α – 8-iso-prostaglandin F2α.
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[2, 12]. some studies have shown that elevated iL-6 plasma 
concentrations are associated with negative inotropic ef-
fects and myocardial damage after reperfusion [15]. These 
studies are consistent with our findings. We also observed 
a significant increase of iL-6 after CABG, which was also 
irrespective of the type of cardioplegia. 
Several strategies are still being introduced to cardiac 
surgery and anesthetic techniques to reduce the signs of 
the inflammatory response and oxidative stress [4, 9, 16]. 
These include, among others, reintroduction of off-pump 
CABG surgery during the first decade of the 21st century 
and introduction of different types of cardioplegia. The im-
pact of cardiopulmonary bypass on systemic inflammation 
remains a matter of debate. Our previous study validated 
the concept that mechanisms other than cardiopulmonary 
bypass are responsible for the increased postoperative in-
flammatory response [8]. 
Little is known about the effects of blood and crystal-
loid cardioplegia on the systemic inflammatory response 
as well as the level of oxidative stress, and the results are 
inconclusive [4–6, 9]. The current findings provide evidence 
that there is no difference in systemic inflammatory re-
sponse and level of oxidative stress between blood and 
crystalloid cardioplegia. Besides, among analyzed markers, 
only preoperative concentration of 8-iso-PGF2α positively 
correlated with occurrence of PMI and in-hospital mortality. 
On the other hand, we did not observe a correlation of PMI 
or mortality with type of cardioplegia. These conclusions 
appear to be similar to other studies [17, 18]. In contrast 
to our outcomes, other authors observed a significant de-
crease of at least one analyzed clinical end point after using 
blood cardioplegia [19, 20]. Thus, the literature is far from 
conclusive, and additional studies are needed to assess the 
superiority of one cardioplegia over another. These discrep-
ancies in the results could be explained at least partially by 
some differences in the composition of cardioplegic solu-
tions, various patient characteristics and slightly different 
criteria for the diagnosis of PMI. 
This study has several limitations. It is an analysis of 
data collected in a single center. The sample size of the 
analyzed group was limited and restricted to CABG pa-
tients. The iL-6, fibrinogen, CRP and 8-iso-PGF2α concen-
trations were measured just at two or three time points. It 
is likely that a stricter measurement schedule, with more 
time points, could more precisely visualize time-dependent 
changes in studied markers. The patients were enrolled 
before 2011, when a new model of risk evaluation was de-
veloped, and for all of them eurosCORe i was calculated. 
The eurosCORe i values were low as only elective, iso-
lated CABG patients, without previous history of cardiac 
surgery and without renal or liver function impairment, 
were recruited. Thus, the results of this study cannot be 
extrapolated to high-risk or urgent patients, in whom an 
acute phase reaction is usually more powerful. Also, the 
influence of coronary artery disease severity and epicardial 
blood flow as well as platelet activation on the inflamma-
tory response in different cardioplegia strategies was not 
analyzed [21–25]. The low incidence of PMi and in-hospital 
Tab. IV. Changes of studied inflammatory response and oxidative stress parameters in patients with analyzed clinical endpoints
Variable All patients
(N = 238)
Patients 
without PMI
(n = 218)
Patients 
with PMI
(n = 20)
P-value Survivors
(n = 230)
In-hospital 
death
(n = 8)
P-value
iL-6 [pg/ml]:
At baseline
2.1 
(1.1–4.0)
2.0 
(1.2–4.6)
3.3 
(1.9–3.9)
0.536
2.0 
(1.1–3.9)
3.7 
(2.6–4.4)
0.491
5–7-days after CABG
14.6 
(5.2–23.9)
14.4 
(5.9–22.1)
18.8 
(11.2–32.7)
0.030
14.5 
(5.2–23.8)
36.5 
(18.2–49.7)
0.242
Fibrinogen [g/l]:
At baseline 4.2 ±1.2 4.2 ±1.2 4.5 ±1.1 0.283 4.2 ±1.2 4.2 ±0.9 0.948
18–36 h after CABG 6.3 ±1.7 5.5 ±1.7 6.0 ±1.9 0.398 5.6 ±1.7 5.6 ±1.7 0.997
5–7-days after CABG 7.1 ±1.4 7.1 ±1.4 6.5 ±1.7 0.355 7.1 ±1.4 5.7 ±0.9 0.081
CRP [mg/l]:
At baseline
2.3 
(1.5–4.7)
2.3 
(1.5–4.6)
2.6 
(1.6–5.1)
0.958
2.2 
(1.5–4.6)
3.3 
(2.2–12.6)
0.546
18–36 h after CABG
145.5 
(102.2–183.8)
144.3 
(101.7–181.0)
170.4 
(149.1–193.9)
0.213
144.8 
(101.9–181.2)
181.6 
(168.6–212.3)
0.072
5–7-days after CABG
50.3 
(28.3–80.5)
48.3 
(27.8–73.0)
85.3 
(67.2–94.1)
0.174
49.2 
(28.3–75.4)
94.0 
(44.5–96.1)
0.265
8-iso-PGF2α [pg/ml]:
At baseline 358.4 ±39.3 355.6 ±37.2 388.6 ±50.3 0.003 356.4 ±37.8 407.7 ±48.1 0.001
18–36 h after CABG 466.9 ±42.5 463.08 ±37.3 505.6 ±67.5 < 0.001 463.8 ±39.2 545.4 ±51.2 < 0.001
5–7-days after CABG 417.2 ±47.8 409.5 ±37.4 539.6 ±15.5 < 0.001 412.8 ±42.4 538.0 ±21.0 < 0.001
Values are displayed as mean ± standard deviation or median with inter-quartile range. iL-6 – interleukin 6, CABG – coronary artery bypass graft surgery, 
CRP – C-reactive protein, 8-iso-PGF2α – 8-iso-prostaglandin F2α.
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mortality in our study render these clinical outcomes less 
reliable. Clinical aspects of different cardioplegia strategies 
were beyond the scope of this study, since a much larger 
cohort should be recruited for such analysis. Finally, our 
study was limited to the hospital stay. Long-term follow-up 
might provide new insights into the associations between 
the degree of oxidative stress and perioperative inflamma-
tory response and prognosis after CABG surgery.
Conclusions
Our study extends previous reports by showing that the 
type of cardioplegia does not affect specifically the system-
ic inflammatory response as well as oxidative stress reflect-
ed by changes in iL-6, fibrinogen, CRP and 8-iso-PGF2α fol-
lowing the CABG procedure. To our knowledge, this study 
is the first to assess these variables in patients undergo-
ing CABG using different types of cardioplegia. it might be 
speculated that preoperative screening of oxidative stress 
could be helpful in identifying patients at increased risk of 
an unfavorable post-CABG course. Further, larger studies 
are needed to validate our observations. 
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